✦ LIBER ✦

High-dose cyclophosphamide without stem cell rescue for refractory multifocal motor neuropathy

✍ Scribed by Thomas H. Brannagan III; Armin Alaedini; Douglas E. Gladstone

Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 82 KB
Volume: 34
Category: Article
ISSN: 0148-639X
DOI: 10.1002/mus.20524

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High-dose cyclophosphamide therapy witho

High-dose cyclophosphamide therapy without stem cell rescue for severe refractory autoimmune illnesses: Comment on the article by Moore et al

✍ Ann A. Prestrud; Susan Hoch; Isadore Brodsky; Douglas E. Gladstone 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB 👁 2 views

In a recent article (1), Chapman et al described a genetic linkage of primary hip osteoarthritis (OA) with restricted areas on chromosome 11q. This is an elegant study, which may well provide important new insights into hip OA. Nonetheless, I would like to raise concerns about their choice of patien

A Phase I dose escalation trial of conti

A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma

✍ Todd M. Zimmerman; David L. Grinblatt; Rebecca Malloy; Stephanie F. Williams 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 2 views

## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou